

AMENDMENTS TO THE CLAIMS

Claim 1 (cancelled).

Claim 2 (original). A pharmaceutical composition, comprising an agent with tumor-inhibiting activity, which is selective for cells expressing or abnormally expressing a tumor-associated antigen, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:

(a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOS.: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 105, 109, 113, 117, 121, 125, 129, 133, 137, 141, 145, 149, 153, 157, 161, 165, 169, 173, 175, 179, 183, 187, 191, 195, 199, 203, 207, 211, 215, 219, 223, 227, 231, 235, 239, 243, 247, 251, 255, 259, 263, 267, 269, 271, 273, 275, 277, 279, 309 of the sequence listing, a part or derivative thereof,

(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,

(c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and

(d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).

Claim 3 (original). The pharmaceutical composition as claimed in claim 2, in which the agent causes induction of cell death, reduction in cell growth, damage to the cell membrane or secretion of cytokines.

Claim 4 (currently amended). The pharmaceutical composition as claimed in claim ~~1~~ or 2, in which the agent is an antisense nucleic acid which hybridizes selectively with the nucleic acid coding for the tumor-associated antigen.

Claim 5 (currently amended). The pharmaceutical composition as claimed in claim ~~1~~ or 2, in which the agent is an antibody which binds selectively to the tumor-associated antigen.

Claim 6 (original). The pharmaceutical composition as claimed in claim 2, in which the agent is a complement-activating antibody which binds selectively to the tumor-associated antigen.

Claims 7-9 (cancelled).

Claim 10 (original). A pharmaceutical composition, comprising one or more components selected from the group consisting of:

- (i) a tumor-associated antigen or a part thereof,
 - (ii) a nucleic acid which codes for a tumor-associated antigen or a part thereof,
 - (iii) an antibody which binds to a tumor-associated antigen or a part thereof,
 - (iv) an antisense nucleic acid which hybridizes specifically with a nucleic acid coding for a tumor-associated antigen,
 - (v) a host cell which expresses a tumor-associated antigen or a part thereof,
- and
- (vi) isolated complexes between a tumor-associated antigen or a part thereof and an HLA molecule,

said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:

- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 105, 109, 113, 117, 121, 125, 129, 133, 137, 141, 145, 149, 153, 157, 161, 165, 169, 173, 175, 179, 183, 187, 191, 195, 199, 203, 207, 211, 215, 219, 223, 227, 231, 235, 239, 243, 247, 251, 255, 259, 263, 267, 269, 271, 273, 275, 277, 279, 309 of the sequence listing, a part or derivative thereof,
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).

Claims 11-19 (cancelled).

Claims 20 (currently amended). The pharmaceutical composition as claimed in claim ~~5~~ or 10, in which the antibody is a monoclonal antibody.

Claim 21 (currently amended). The pharmaceutical composition as claimed in claim ~~5~~ or 10, in which the antibody is a chimeric or humanized antibody.

Claim 22 (currently amended). The pharmaceutical composition as claimed in claim ~~5~~ or 10, in which the antibody is a fragment of a natural antibody.

Claim 23 (currently amended). The pharmaceutical composition as claimed in claim ~~5~~ or 10, in which the antibody is coupled to a therapeutic or diagnostic agent.

Claim 24 (currently amended). The pharmaceutical composition as claimed in claim ~~4~~ or 10, in which the antisense nucleic acid comprises a sequence of 6-50 contiguous nucleotides of the nucleic acid coding for the tumor-associated antigen.

Claims 25-26 (cancelled).

Claim 27 (currently amended). The pharmaceutical composition as claimed in ~~any of claims 1-26~~ claim 10, further comprising a pharmaceutically acceptable carrier and/or an adjuvant.

Claims 28-56 (cancelled).

Claim 57 (original). A method of treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of a tumor-associated antigen, which method comprises administering an antibody binding to said tumor-associated antigen or to a part thereof and coupled to a therapeutic or diagnostic agent, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:

(a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 105, 109, 113, 117, 121, 125, 129, 133, 137, 141, 145, 149, 153, 157, 161, 165, 169, 173, 175, 179, 183, 187, 191, 195, 199, 203, 207, 211, 215, 219, 223, 227, 231, 235, 239, 243, 247, 251, 255, 259, 263, 267, 269, 271, 273, 275, 277, 279, 309 of the sequence listing, a part or derivative thereof,

(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,

(c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and

(d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).

Claim 58 (currently amended). The method as claimed in claim ~~42, 50~~ or 57, in which the antibody is a monoclonal antibody.

Claim 59 (currently amended). The method as claimed in claim ~~42, 50 or 57~~, in which the antibody is a chimeric or humanized antibody.

Claim 60 (currently amended). The method as claimed in claim ~~42, 50 or 57~~, in which the antibody is a fragment of a natural antibody.

Claims 61-73 (cancelled).

Claim 74 (original). A nucleic acid, which codes for a protein or polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 2,6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, 94, 98, 102, 106, 110, 114, 118, 122, 126, 130, 134, 138, 142, 146, 150, 154, 158, 162, 166, 170, 174, 176, 180, 184, 188, 192, 196, 200, 204, 208, 212, 216, 220, 224, 228, 232, 236, 240, 244, 248, 252, 256, 260, 264, 268, 270, 272, 274, 276, 278, 280 to 308, 310 of the sequence listing, a part or derivative thereof.

Claims 75-82 (cancelled).

Claim 83 (original). A protein or polypeptide, which comprises an amino acid sequence selected from the group consisting of SEQ ID NOS.: 2,6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, 94, 98, 102, 106, 110, 114, 118, 122, 126, 130, 134, 138, 142, 146, 150, 154, 158, 162, 166, 170, 174, 176, 180, 184, 188, 192, 196, 200, 204, 208, 212, 216, 220, 224, 228, 232, 236, 240, 244, 248, 252, 256, 260, 264, 268, 270, 272, 274, 276, 278, 280 to 308, 310 of the sequence listing, a part or derivative thereof.

Claims 84-94 (cancelled).

Claim 95 (original). A kit for detecting expression or abnormal expression of a tumor-associated antigen, which kit comprises agents for detection

(I) of the nucleic acid which codes for the tumor-associated antigen or of a part thereof,

(ii) of the tumor-associated antigen or of a part thereof,

(iii) of antibodies which bind to the tumor-associated antigen or to a part thereof, and/or

(iv) of T cells which are specific for a complex between the tumor-associated antigen or a part thereof and an MHC molecule, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:

(a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOS.: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69,

73, 77, 81, 85, 89, 93, 97, 101, 105, 109, 113, 117, 121, 125, 129, 133, 137, 141, 145, 149, 153, 157, 161, 165, 169, 173, 175, 179, 183, 187, 191, 195, 199, 203, 207, 211, 215, 219, 223, 227, 231, 235, 239, 243, 247, 251, 255, 259, 263, 267, 269, 271, 273, 275, 277, 279, 309 of the sequence listing, a part or derivative thereof,

(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,

(c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and

(d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).

Claim 96 (original). The kit as claimed in claim 95, in which the agents for detection of the nucleic acid which codes for the tumor-associated antigen or of a part thereof are nucleic acid molecules for selective amplification of said nucleic acid.

Claims 97-114 (cancelled).